Frequency, Management, And Resource Use Of Adverse Events (Aes) In Nonmetastatic Castrate-Resistant Prostate Cancer (Nmcrpc) Patients Receiving Apalutamide Or Enzalutamide: A Real-World Study.

Shan Jiang,Della Varghese,Sreevalsa Appukkuttan,Shelby Corman,Nehemiah Kebede,Kajan Gnanasakthy,Cynthia Macahilig,A. Reginald Waldeck,Arif Hussain

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览1

暂无评分

摘要

217Background: Second generation androgen receptor inhibitors (SGARIs), apalutamide (APA) and enzalutamide (ENZ) and darolutamide, are approved in the United States (US) for the treatment of nmCRPC...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要